Transplacental Chikungunya Virus Antibody Kinetics, Thailand by Watanaveeradej, Veerachai et al.
Transplacental
Chikungunya Virus
Antibody Kinetics,
Thailand
Veerachai Watanaveeradej,*1 Timothy P. Endy,†1
Sriluck Simasathien,* Angkool Kerdpanich,*
Napuschon Polprasert,* Chanchai Aree,* 
David W. Vaughn,‡ and Ananda Nisalak§
Antibodies to chikungunya virus were detected by
hemagglutination-inhibition assay in 33.6% of 2,000
infants’ cord sera at delivery. Follow-up of 24 seropositive
infants showed that the half-life of antibody persistence
was 35.5 days. Chikungunya virus infection is common in
Thailand, and routine use of diagnostic assays is needed.
C
hikungunya virus (CHIKV, family Togaviridae, genus
Alphavirus) was first isolated during an epidemic in
Tanzania in 1952 and 1953 (1). CHIKV disease can mani-
fest as a syndrome involving fever, rash, and arthralgia
syndrome (2) and can produce clinical signs and symptoms
that are difficult to distinguish from those of dengue fever
or dengue hemorrhagic fever. CHIKV and dengue virus
(DENV) are both transmitted by Aedes mosquitoes, such
as A. aegypti and A. albopictus. Thus, many risk factors for
CHIKV and DENV infections are similar. The diagnosis of
dengue in Thailand is made primarily by clinical symp-
toms and a complete blood count according to World
Health Organization guidelines. However, the major clini-
cal features of dengue overlap with those of other causes
of febrile illnesses (3). In addition, denguelike illness has
occasionally been reported in patients without evidence of
anti-dengue antibody seroconversion (4,5).
The objectives of this study were to assess the sero-
prevalence of antibodies to CHIKV in a sample of preg-
nant women and the kinetics of transplacentally
transferred antibodies to CHIKV. This is the first study of
serologic features of CHIKV in a large Thai sample. We
also examined antibodies to dengue viruses in the same
sample (6) to increase our understanding of the epidemio-
logic features of both diseases.
The Study
Two thousand pregnant women with uncomplicated
pregnancies at the time of delivery at the Phramongkutklao
Hospital from March 1998 through October 1999 gave
informed consent to participate in this study. Antibody
titers to CHIKV were measured by hemagglutination-inhi-
bition (HI) assay in all 2,000 cord serum samples.
Antibodies in cord blood are transferred from the mother
and can reflect previous infection. Asubset of 250 mothers
and their infants were enrolled to compare the rate of trans-
fer of maternal antibodies. Within this subset, 101 infants
had serial serum sampling at 1, 2, 4, 6, 9, 12, 15, and 18
months of age.
HI titers to CHIKV and DENV were determined at the
Armed Forces Research Institute of Medical Sciences,
Bangkok, Thailand. Assays were performed according to
the method of Clarke and Casals, modified for the
microtiter system for each virus as previously described
(6,7). HI titers >10 were considered positive. CHIKV is
the only alphavirus known to circulate in Thailand; anti-
bodies to other alphaviruses were not expected in this
study, nor were they assayed. However, Ross River virus,
Getah virus, Sindbis virus, and Bebaru virus have been
reported to circulate in countries that border Thailand (1).
The mean age of the 2,000 mothers was 26.4 years
(range 15–45 years). Most volunteers (79.9%) lived in
Bangkok. Of these, 672 (33.6%) and 1,937 (96.9%) were
seropositive for CHIKV and DENV, respectively. The
seroprevalence of antibodies to CHIKV increased with age
(Figure 1), and ≈47% of mothers >35 years of age were
seropositive to CHIKV. The degree of CHIKV-specific
antibodies transferred to infants was determined in 250
randomly selected mother-infant pairs. Of 250 mothers, 79
(31.6%) were seropositive for CHIKV, and 64 (81.0%) of
these mothers transferred antibodies to their babies. We
compared HI titers between mothers and cord sera; 58%
had the same titers, 31% of cord sera had higher titers, and
11% of cord sera had lower titers. This finding was consis-
tent with an active transport mechanism across the placen-
ta. Similar findings were reported for DENV-specific
antibodies (6,8). Fifteen (19%) infants born to seropositive
mothers did not have detectable titers of antibodies to
CHIKV.
Of the 79 mothers who were seropositive to CHIKV, 28
agreed to further follow-up study; their infants were fol-
lowed up until 18 months of age. Four infants were nega-
tive on cord blood testing and remained negative until 18
months of age. Of 24 infants whose cord blood was posi-
tive, 8.3%, 33.3%, 87.5%, and 100% lost their antibodies
to CHIKV by 2, 4, 6, and 9 months of age, respectively.
The half-life of antibody to CHIKV was calculated by
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linear and logarithmic scales. Using SPSS software (SPSS
Inc., Chicago, IL, USA), we calculated the line of best fit
by exponential regression (Figure 2). From this curve, we
calculated the half-life of maternal antibodies to CHIKV in
infants to be 35.5 days.
Conclusions
In Thailand, after the first reported cases of CHIKV
infection were confirmed by serologic analysis in 1960 (9),
a serosurvey was conducted in 1976 in a rural population
with an overall antibody prevalence of 24.6% that increased
with age (10). The higher prevalence seen in this study
(33.6%) might be explained by a larger sample that is more
capable of sustaining transmission and increased vectors. A
nationwide serologic study of both DENV and CHIKV in
Thai patients took place in 1974–1976. This study sug-
gested that CHIKV was not a substantial health problem
(11). Disease caused by CHIKV, unlike DENV, is not a
reportable disease, and laboratory diagnosis is not routinely
available. As a result, it is probably underreported, which
would reduce physicians’ index of suspicion, resulting in
further underreporting. However, epidemics of CHIKV dis-
ease in Thailand have been periodically documented.
The clinical-to-subclinical ratio was 1:1 to 1:6 for
DENV infection (12) and was ≈1.8:1 for CHIKV infection
(C.G. Beckett, pers. comm.). This report shows the reemer-
gence of CHIKV infection in Thailand; the ratio of sero-
prevalence of DENV infection to CHIKV infection was
2.9:1. National surveillance reported 130,000 dengue ill-
nesses in 1998 (13). If the ratio is applied, we can estimate
>44,000 persons infected with CHIKV in the same year.
Therefore, infection with this virus may be more common
than is believed. In a previous study of Thai children hos-
pitalized with presumptive dengue hemorrhagic fever,
≈20% of diagnoses were ultimately changed to acute
CHIKV infection (4).
Antibodies to CHIKV in infants’ circulation may pro-
tect them from the illness until 9 months of age. This find-
ing is consistent with the observation that denguelike
illness is rarely seen in infants. A vaccine for CHIKV is
still in early stages of development (14); the 9-month per-
sistence of antibodies to CHIKV provides insight to the
optimal age of vaccination, should a vaccine become avail-
able. This study shows substantial CHIKV circulation in a
DENV-endemic country. Since signs and symptoms of the
disease are similar, surveillance for viruses and the dis-
eases they cause should be developed and maintained.
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chikungunya
From the language of the Makonde, northern Mozambique
and southeast Tanzania (often misattributed to Swahili),
“that which bends up.” Chikungunya refers to the stooped
posture that develops as a result of arthritic symptoms. A
self-limiting disease, chikungunya is caused by an
alphavirus spread by the bite of Aedes mosquitoes. Though
not generally fatal, the disease can be severe. Awidespread
outbreak in islands of the Indian Ocean, begun in February
2005, has caused >200 deaths.
Sources: Dorland's illustrated medical dictionary. 30th ed. Philadelphia:
Saunders; 2003 and wikipedia.org
e et ty ym mo ol lo og gi ia a